The influence of hereditary factors on clinical course and treatment outcome in lung cancer

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

According to clinical, clinicogenealogical and molecular genetic studies, the conception of two general pathogenic lung cancer types - hereditary and ecological - was proposed and theoretically proved. Malignant lung tumors of hereditary type tend to be more aggressive in comparison with ecological type. They are characterized by high level of invasion to adjacent organs and high metastatic potential, both to lymph nodes and distant organs, mostly owing to multiple metastases. Biological features of hereditary pathological lung cancer type have a great effect on surgical treatment. Patients with disease burdened with hereditary factors have at least 10% less chance to undergo a radical operation. Extended operations are performed more common for this patients than wedge resection. 5 year survival for patients with hereditary type lung cancer is 1,8 times lower than for those with ecological type.

About the authors

R. Vagner

N. N. Petrov Research Institute of Oncology

Author for correspondence.
Email: shabanov@mail.rcom.ru

Член-корреспондент РАМН 

Russian Federation, St. Petersburg

A. Barchuk

N. N. Petrov Research Institute of Oncology

Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg

E. Imyanitov

N. N. Petrov Research Institute of Oncology

Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg

V. Shutkin

N. N. Petrov Research Institute of Oncology

Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg

References

  1. Вагнер Р. И., Шуткин В. А., Барчук А. С. Особенности регионарного метастазирования рака легкого у больных с отягощенным наследственным фактором // Вопр. онкол. 1994. Т. 40. №1-2-3. С. 25-29.
  2. Вагнер Р. И., Шуткин В. А., Барчук А. С. Хирургическое лечение больных раком легкого с отягощенной наследственностью // Вестн. хир. 1995. Т. 154. №1. С. 41-44.
  3. Мерабишвили В. М., Дятченко О. Т. Статистика рака легкого (заболеваемость, смертность, выживаемость) // Практ. онкол. 2000. Т. 3. С. 37.
  4. Fernandez P. et al. Distinctive gene expression of human lung adenocarcinomas carrying LKB1 mutations // Oncogene. 2004. Vol. 23. P. 5084-5091.
  5. Fischer J. R. and Lahm H. Validation of molecular and immunological factors with predictive importance in lung cancer // Lung Cancer. 2004. Vol. 45 (Suppl. 2). P. S151-S161.
  6. Forgacs E. et al. Molecular genetic abnormalities in the pathogenesis of human lung cancer // Pathol. Oncol. Res. 2001. Vol. 7. P. 6-13.
  7. Hung R. J., Boffetta H., Brockmoller J. et al. CYP1A1 and GSTM genetic polymorphisms and lung cancer risk in Caucasian nonsmokers: a pooled analysis // Carcinogenesis. 2003. Vol. 24. P. 875-882.
  8. Imyanitov E., Hanson K., Zhivotovsky B. Polymorphic variations in apoptotic genes and cancer predisposition // Cell Death Differ. 2005b. Vol. 12. P. 1004-1107.
  9. Imyanitov E. N., Kuligina E. Sh., Belogubova E. V., Togo A. V., Hanson K. P. Mechanisms of lung cancer // Drug Discov. Today: Dis. Mech. 2005a. Vol. 2. P. 213-223.
  10. Imyanitov E.N., Togo A.V., Hanson K.P. Searching for cancer-associated gene polymorphisms: promises and obstacles // Cancer Lett. 2004. Vol. 204. P. 3-14.
  11. Kaye F. J. Molecular biology of lung cancer // Lung Cancer. 2001. Vol. 34 (Suppl. 2). P. S35-S41.
  12. Kishimoto M. et al. Mutations and deletions of the CBP gene in human lung cancer // Clin. Cancer Res. 2005. Vol. 11. P. 512-519.
  13. Kong F. M. et al. M6P/IGF2R is mutated in squamous cell carcinoma of the lung // Oncogene. 2000. Vol. 19. P. 1572-1578.
  14. Ma P. C. et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer // Cancer Res. 2005. Vol. 65. P. 1479-1488.
  15. Mariatos G. et al. Inactivating mutations targeting the chfr mitotic checkpoint gene in human lung cancer // Cancer Res. 2003. Vol. 63. P. 7185-7189.
  16. Nishioka M. et al. MYO18B, a candidate tumor suppressor gene at chromosome 22q12.1, deleted, mutated, and methylated in human lung cancer // Proc. Natl. Acad. Sci. USA. 2002. Vol. 99. P. 12269-12274.
  17. Shigematsu H. et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers // J. Natl. Cancer Inst. 2005. Vol. 97. P. 339-346.
  18. Stephens P. et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours // Nature. 2004. Vol. 431. P. 525-526.
  19. Wagner R., Shutkin V. Hereditary and ecological pathogenic variants of lung cancer // Abstracts of 7th International Congress on Anti-Cancer Treatment. Paris, France. 1997, February 3-6. P. 413.
  20. Wagner R., Shutkin V. Hereditary factor and its effect on course and prognosis of lung cancer // Abstracts of 17th International Cancer Congress. Rio de Janeiro, Brazil. 1988, August 23-28. P. 611-614.
  21. Wagner R., Shutkin V. The results of surgical treatment of patients with lung cancer of various pathogenic variants // Abstracts of International Congress of Thorax Surgery. Athens, Greece. 1997, July 1-8. P. 196.
  22. Wynder E., Hoffman D. Smoking and lung cancer: challenges and opportunities // Cancer Res. 1997. Vol. 54. P. 1580-1586.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.